Spirulina.Guru

Science

Spirulina and primary biliary cholangitis.

Primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) is an autoimmune liver disease in which intrahepatic bile ducts are destroyed by autoreactive T cells and NK cells recognising mitochondrial antigens on cholangiocytes. Cholangiocyte NOX2 activation amplifies the inflammatory biliary infiltrate. The fatigue that affects 80% of PBC patients — and which UDCA does not treat — is partly addressable by spirulina’s nutritional and anti-inflammatory mechanisms.

PBC pathophysiology

  • Anti-mitochondrial antibodies (AMA): AMAs against the E2 subunit of pyruvate dehydrogenase complex (PDC-E2) are present in >95% of PBC patients. Cholangiocytes uniquely apoptose by presenting PDC-E2 on their surface, making them targets for T cells that cross-react with the mitochondrial antigen. NK cells are recruited to the biliary infiltrate and contribute to cholangiocyte destruction.
  • Cholangiocyte NOX2: Biliary epithelial cells express NOX2. Inflammatory cytokines (IFN-γ, TNF-α) from infiltrating T and NK cells upregulate cholangiocyte NOX2, generating superoxide that activates NF-κB and drives further cytokine production. This amplifies the biliary inflammatory cycle. Phycocyanobilin’s NOX2 inhibition may reduce this oxidative amplification of biliary inflammation.
  • NK cell concern: NK cells are part of the primary cellular infiltrate causing biliary destruction in PBC. Spirulina’s NK stimulation is therefore a relevant concern in PBC, similar to its concern in alopecia areata (where NK cells are also primary effectors). Discuss with hepatologist before starting spirulina in PBC.

Fatigue in PBC: spirulina mechanisms

  • Fatigue affects 80% of PBC patients and is the most disabling symptom. UDCA, the primary treatment for PBC, improves liver biochemistry and slows histological progression but does not improve fatigue. Obeticholic acid (OCA) similarly does not address fatigue.
  • Fatigue mechanisms in PBC include: autonomic dysfunction, sleep disruption from pruritus, iron deficiency anaemia (common from chronic disease + reduced hepatic iron processing), and central inflammatory neurotransmitter dysregulation (elevated IL-6 in PBC correlates with fatigue severity).
  • Spirulina addresses several fatigue contributing factors: iron (non-haem, 2–4 mg/5 g), complete protein for mitochondrial substrates, and phycocyanobilin reducing IL-6 production via NF-κB inhibition.

Fat-soluble vitamin malabsorption

  • In advanced PBC with significant cholestasis, bile acid deficiency in the small bowel impairs fat-soluble vitamin (A, D, E, K) absorption. Spirulina’s beta-carotene (pro-vitamin A, ~1,500–2,000 µg/5 g) and vitamin K content may have reduced bioavailability in severe cholestasis. In decompensated PBC: specialist-directed fat-soluble vitamin supplementation (water-miscible forms) is more reliable than spirulina for addressing specific deficiencies.
  • Warfarin interactions in PBC: vitamin K from spirulina (~20–30 µg/10 g) requires consistent daily dosing and INR check 2 weeks after starting, as in other warfarin contexts.

Drug interactions

Ursodeoxycholic acid (UDCA)

  • UDCA is the standard first-line treatment in PBC (13–15 mg/kg/day). It replaces toxic endogenous bile acids and has hepatoprotective effects. UDCA is not significantly CYP-metabolised. No documented pharmacokinetic interaction with spirulina. Take spirulina at a different time to UDCA to avoid any potential bile acid-mediated absorption competition.

Obeticholic acid (OCA)

  • OCA is an FXR agonist used as second-line in UDCA-incomplete responders. No CYP-significant interaction with spirulina documented. OCA causes pruritus in many patients; spirulina GLA pathway may modestly reduce leukotriene-mediated itch, which could be mildly helpful in OCA-induced pruritus — though no data exists.

Bezafibrate (PBC second-line in some countries)

  • Bezafibrate (PPAR-α agonist) is used in PBC in Japan and some European centres. No documented interaction with spirulina. Bezafibrate and spirulina both have lipid-modifying effects (additive triglyceride reduction, HDL improvement).

Practical guidance

  • PBC on UDCA ± OCA: discuss NK stimulation concern with hepatologist before starting spirulina; NK cells are key biliary infiltrate effectors in PBC
  • If approved: 1–2 g/day initially; increase to 3–5 g/day over 4–6 weeks if no biochemical change in liver enzymes; recheck LFTs 6–8 weeks after starting
  • Fatigue: iron status (transferrin saturation, not ferritin) and protein adequacy are the most addressable nutritional contributors; spirulina provides both
  • Advanced PBC with cholestasis: water-miscible fat-soluble vitamins preferred over relying on spirulina beta-carotene/vitamin K

Related reading

Get the weekly digest

Curated science, recipes, and brand intel — once a week, no spam, unsubscribe in one click.